Navigation Links
Stroke Treatment Based on Traditional Chinese Medicine Increases Chances of Recovery
Date:6/20/2013

SINGAPORE, June 20, 2013 /PRNewswire/ -- NeuroAiD, a stroke treatment based on Traditional Chinese Medicine, increases the odds of achieving a better functional outcome, according to research published online in the journal Stroke.

The CHIMES study is an academic international double-blind placebo-controlled clinical trial which included 1,100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, treated and monitored for 3 months. Researchers found that patients who were taking NeuroAiD at acute stage had an 11% increase in the odds of achieving independence in function and being able to perform daily activities at the end of three months. This effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.

The odds ratio was the highest among recently completed stroke trials of neuroprotective agents. The benefit observed is clinically relevant and might have reached statistical significance with a larger sample size. In addition the study confirmed the excellent safety profile of NeuroAiD. Stroke survivors who were on NeuroAiD had fewer adverse events than those in the control group. Further studies will likely look into the benefits of longer duration of treatment.

Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study, said the results looked very promising and suggested that the effectiveness of such herbal supplements could have a great impact on stroke management. "I think one thing which is very clear is that NeuroAiD is safe in acute stroke.  A previous meta-analysis suggested that NeuroAiD is efficacious and safe in the chronic stage of stroke. Now the Chimes study has provided us with much more reliable data about the safety and efficacy of NeuroAiD in acute stroke. I think the CHIMES result
'/>"/>

SOURCE Moleac
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Treatment for Stroke Set to Increase Chances of Recovery
2. Quincy Valley Medical Center Launches New Robotic Telestroke Program
3. NeuroAiD(TM), a Stroke Treatment Based on Traditional Chinese Medicine, More than Doubles the Chances of Achieving Independence after Stroke
4. Niacin Causes Serious Unexpected Side-effects, but no Worthwhile Benefits, for Patients who are at Increased Risk of Heart Attacks and Strokes
5. Now Available in Fredericksburg: Painless Screening Exam To Help Prevent Heart Attacks, Strokes
6. Top New York City Cardiologist Dr. Steven Reisman to be Featured on Inside Edition to Discuss Mini-Strokes and Strokes
7. New "15 Every Hour" Campaign Spreads the Word on the Devastating Impact of AFib-Related Stroke
8. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
9. Masimos Noninvasive Pleth Variability Index as Accurate as Invasive Stroke Volume Variation for Fluid Responsiveness Assessment in Cardiac Surgery
10. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
11. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... 22, 2014  AbbVie (NYSE: ABBV ... evaluating potential new medicines in the company,s oncology ... European Society of Medical Oncology (ESMO) Annual Congress, ... . Data being presented include results from a ... of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) ...
(Date:9/22/2014)... CAMBRIDGE, Mass. , Sept. 22, 2014  Seres ... diseases related to the human microbiome, today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Amid a great ... out for its focus and commitment to practical therapeutic ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Barry Edison announces that Barry Edison Ophthalmology in ... Pelleve® Wrinkle Reduction System, a revolutionary skin-tightening system ... uses Pelleve—an advanced radiofrequency technology—because the treatment delivers ... results. "I am proud to now offer Pelleve ...
... 22, 2012  Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... Phase 3 trial evaluating Nexavar ® (sorafenib) tablets ... cell lung cancer (NSCLC) whose disease progressed after two ... endpoint of improving overall survival.  An improvement in the ...
Cached Medicine Technology:New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 3Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 4Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 5Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 6
(Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , which ... bursitis treatment in Manhattan. This treatment is now offered at ... which is also called trochanteric bursitis, occurs when the ... a fluid-filled sac in the hip, between the iliotibial ...
(Date:9/22/2014)... The concept of a whole eye transplant seems ... grant from the U.S. Department of Defense, researchers ... Medicine hope to someday make implantation of an ... eye transplant could be a holy grail for ... of ophthalmology and grant co-recipient with colleagues at ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... MDAn original and progressive report on health information ... online today, makes ground-breaking recommendations for new ... tensions that currently mar relationships between many HIT ... indemnity and error management of HIT systems. In ...
... November 11, 2010 A new study from researchers in ... more likely to undergo a screening colonoscopy than those who ... for female endoscopists seem to be common among women. In ... notion that rates of screening colonoscopy can be increased by ...
... , THURSDAY, Nov. 11 (HealthDay News) -- U.S. ... to binge-drink, smoke cigarettes or use illicit drugs, a new ... likely to abuse prescription drugs, according to the Center ... from an analysis of 2002 to 2009 data from the ...
... in French . , Montreal, November 11, 2010 ... additional cardiac test when undergoing diagnosis for potential heart problems, ... du Qubec Montral and the Montreal Heart Institute. ... Journal of Cardiopulmonary Rehabilitation and Prevention , a large sample ...
... By Jenifer Goodwin HealthDay Reporter , ... synthetic marijuana known as "K2" is sending young people ... and hallucinations, toxicologists warn. In recent months, physicians ... up in emergency rooms after smoking synthetic marijuana. Despite ...
... chemist Dr Guillaume Lessene has been awarded the Walter and ... annual general meeting in Melbourne, Australia. The $AUD150,000 ... played in shaping the Walter and Eliza Hall Institute. It ... Burgh in August at the age of 94. ...
Cached Medicine News:Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 2Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Additional cardiac testing vital for patients with anxiety and depression 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Medicinal chemist wins inaugural De Burgh Fellowship 2
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: